Genetic alterations and targeted therapies in salivary gland neoplasms. (PubMed, Sci Prog) - Sep 16, 2026 - "For instance, pleomorphic adenomas often have PLAG1 overexpression and FGFR1 fusions, activating the IGF and WNT signaling pathways; linsitinib, a dual IGF1R and tyrosine kinase inhibitor, has demonstrated antitumor activity in other malignancies and may hold potential in this context...Further research is needed to validate these findings in clinical trials. Overall, integrating molecular diagnostics with pathway-specific targeted therapies may enhance outcomes and expand treatment options for patients with SGNs."
Journal • Review • Oncology • Salivary Gland Cancer • Solid Tumor • FGFR1 • HER-2 • PLAG1
|
|
Richard V Smith; Sharwani Kota
|